Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

UMBRALISIB for Diffuse large b-cell lymphoma: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 20 adverse event reports in the FDA FAERS database where UMBRALISIB was used for Diffuse large b-cell lymphoma.

Most Reported Side Effects for UMBRALISIB

Side Effect Reports % Deaths Hosp.
Diarrhoea 47 16.0% 2 5
Nausea 36 12.3% 1 5
Disease progression 30 10.2% 2 3
Fatigue 30 10.2% 1 0
Covid-19 16 5.5% 3 13
Nervous system disorder 15 5.1% 0 0
Death 14 4.8% 14 4
Asthenia 13 4.4% 1 2
Off label use 13 4.4% 1 0
Product dose omission issue 12 4.1% 0 3
Anaemia 11 3.8% 0 0
Decreased appetite 11 3.8% 1 2
Pyrexia 11 3.8% 0 0
Dizziness 10 3.4% 0 3
Drug ineffective 10 3.4% 0 0

Other Indications for UMBRALISIB

Chronic lymphocytic leukaemia (66) Non-hodgkin's lymphoma (50) Follicular lymphoma (48) Product used for unknown indication (42) Marginal zone lymphoma (20) B-cell lymphoma (18) Lymphoma (9)

Other Drugs Used for Diffuse large b-cell lymphoma

RITUXIMAB (22,275) CYCLOPHOSPHAMIDE (16,598) DOXORUBICIN (15,213) VINCRISTINE (14,922) PREDNISONE (11,266) LENALIDOMIDE (7,858) ETOPOSIDE (4,698) PREDNISOLONE (4,086) CYTARABINE (3,857) DEXAMETHASONE (3,696)

Related Pages

UMBRALISIB Full Profile All Diffuse large b-cell lymphoma Drugs UMBRALISIB Demographics UMBRALISIB Timeline